Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Bioorg Med Chem ; 28(22): 115746, 2020 11 15.
Artigo em Inglês | MEDLINE | ID: mdl-33007558

RESUMO

Human T cell lymphotropic virus type 1 (HTLV-1) is a human retrovirus that infects approximately 10-20 million people worldwide and causes an aggressive neoplasia (adult T-cell leukemia/lymphoma - ATL). Therapeutic approaches for the treatment of ATL have variable effectiveness and poor prognosis, thus requiring strategies to identify novel compounds with activity on infected cells. In this sense, we initially screened a small series of 25 1,2,3-triazole derivatives to discover cell proliferation inhibitors and apoptosis inducers in HTLV-1-infected T-cell line (MT-2) for further assessment of their effect on viral tax activity through inducible-tax reporter cell line (Jurkat LTR-GFP). Eight promising compounds (02, 05, 06, 13, 15, 21, 22 and 25) with activity ≥70% were initially selected, based on a suitable cell-based assay using resazurin reduction method, and evaluated towards cell cycle, apoptosis and Tax/GFP expression analyses through flow cytometry. Compound 02 induced S phase cell cycle arrest and compounds 05, 06, 22 and 25 promoted apoptosis. Remarkably, compounds 22 and 25 also reduced GFP expression in an inducible-tax reporter cell, which suggests an effect on Tax viral protein. More importantly, compounds 02, 22 and 25 were not cytotoxic in human hepatoma cell line (Huh-7). Therefore, the discovery of 3 active and non-cytotoxic compounds against HTLV-1-infected cells can potentially contribute, as an initial promising strategy, to the development process of new drugs against ATL.


Assuntos
Antivirais/farmacologia , Produtos do Gene tax/antagonistas & inibidores , Compostos Heterocíclicos/farmacologia , Vírus Linfotrópico T Tipo 1 Humano/efeitos dos fármacos , Triazóis/farmacologia , Antivirais/síntese química , Antivirais/química , Pontos de Checagem do Ciclo Celular/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Células Cultivadas , Relação Dose-Resposta a Droga , Produtos do Gene tax/metabolismo , Compostos Heterocíclicos/química , Humanos , Estrutura Molecular , Relação Estrutura-Atividade , Triazóis/química
2.
Biomolecules ; 10(5)2020 05 20.
Artigo em Inglês | MEDLINE | ID: mdl-32443921

RESUMO

In recent years, the number of new antimicrobial drugs launched on the market has decreased considerably even though there has been an increase in the number of resistant microbial strains. Thus, antimicrobial resistance has become a serious public health problem. Amphibian skin secretions are a rich source of host defense peptides, which generally are cationic and hydrophobic molecules, with a broad-spectrum of activity. In this study, one novel multifunctional defense peptide was isolated from the skin secretion of the Chaco tree frog, Boana raniceps. Figainin 2 (1FLGAILKIGHALAKTVLPMVTNAFKPKQ28) is cationic and hydrophobic, adopts an α-helical structure in 50% (v/v) trifluoroethanol (TFE), and is thermally stable. This peptide exhibited activity against Gram-negative and Gram-positive pathogenic bacteria arboviruses, T. cruzi epimastigotes; however, it did not show activity against yeasts. Figainin 2 also showed antiproliferative activity on cancer cells, is moderately active on human erythrocytes, and activates the oxidative burst in human neutrophils.


Assuntos
Proteínas de Anfíbios/metabolismo , Anuros/metabolismo , Defensinas/metabolismo , Pele/metabolismo , Proteínas de Anfíbios/química , Proteínas de Anfíbios/farmacologia , Animais , Arbovírus/efeitos dos fármacos , Bactérias/efeitos dos fármacos , Candida/efeitos dos fármacos , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Células Cultivadas , Defensinas/química , Defensinas/farmacologia , Hemólise/efeitos dos fármacos , Humanos , Neutrófilos/efeitos dos fármacos , Conformação Proteica em alfa-Hélice , Trypanosoma cruzi/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA